


embodiments, methods comprise administering a loading dose of about 40 to about 70 mg of Compound 696844 once about every 4 weeks, and subsequently administering a maintenance dose of about 40 to about 70 mg of Compound 696844 once about every 4 weeks, once about every 8 weeks, once about every 12 weeks, or once about every 24 weeks. In some embodiments, methods
5 comprise administering at least 2 loading doses, at least 3 loading doses, at least 4 loading doses, at least 5 loading doses, or at least 6 loading doses.

In one aspect, there is provided a use of a compound according to the following chemical structure in the manufacture of a medicament for the treatment of IgA Nephropathy in a human subject, wherein a dose comprising about 10 mg to about 100mg of the compound is to be
10 administered to the human subject:



(SEQ ID NO: 4, Compound 696844), or a pharmaceutically acceptable salt thereof.

Description

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive. Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including” as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated-by-reference for the portions of the document discussed herein, as well as in their entirety.

DEFINITIONS


Unless specific definitions are provided, the nomenclature used in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Where permitted, all patents, applications, published applications and other publications and other data referred to throughout in the disclosure are incorporated by reference herein in their entirety.

Unless otherwise indicated, the following terms have the following meanings:

As used herein, “2’-deoxynucleoside” means a nucleoside comprising a 2’-H(H) deoxyribosyl sugar moiety. In certain embodiments, a 2’-deoxynucleoside is a 2’-β-D-deoxynucleoside and comprises a 2’-β-D-deoxyribosyl sugar moiety, which has the β-D ribosyl configuration as found in naturally occurring deoxyribonucleic acids (DNA). In certain

CLAIMS:


1. Use of a compound according to the following chemical structure in the manufacture of a medicament for the treatment of IgA Nephropathy in a human subject, wherein a dose comprising about 10 mg to about 100mg of the compound is to be administered to the human subject:



(SEQ ID NO: 4, Compound 696844), or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the compound is the sodium salt or the potassium salt.

3. The use of claim 1, wherein the compound is the sodium salt of Compound 696844, represented by the following chemical structure:



4. The use of any one of claims 1-3 wherein the dose is a therapeutically effective amount of about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, or about 100 mg.

5. The use of any one of claims 1-3, wherein the dose of the compound is about 70 mg, about 60 to about 70 mg, about 65 to about 75 mg, about 70 to about 75 mg, or about 70 to about 80 mg.
6. The use of any one of claims 1-3, wherein the dose of the compound is equivalent to 70 mg of the fully protonated form of Compound 696844.
7. The use of any of claims 1-6, wherein the dose is to be administered once about every week, once about every two weeks, once about every 3 weeks, once about every 4 weeks, once about every 28 days, once about every month, once about every 8 weeks, once about every two months, once about every 12 weeks, once about every 16 weeks, or once about every 24 weeks.
8. The use of any one of claims 1-6, wherein the dose is to be administered once about every 4 weeks, once about every 28 days, or once about every month.
9. The use of any one of claims 1-6, wherein the dose is to be administered at day 15 or at week 2, and at week 3.
10. The use of any one of claims 1-6 wherein at least 2 doses, , at least 3 doses, at least 4 doses, at least 5 doses, or at least 6 doses of the compound are to be administered.
11. The use of any one of claims 1-6, wherein the dose is to be administered on Day 1, Day 15, and Day 29.
12. The use of any one of claims 1-6, wherein the dose is to be administered on Day 1, Day 15, and Day 29 and once every 4 weeks thereafter.
13. The use of any one of claims 1-6, wherein the dose is to be administered:
 - (i) on Day 1, Day 15, and Day 29; and
 - (ii) once about every 4 weeks, once about every 28 days, or once about every month thereafter.
14. The use of any of claims 1-13, wherein administration of the compound reduces the level of plasma CFB protein, reduces serum AP activity, reduces the level of serum functional

CFB, reduces the level of urinary Factor B split product (Ba), or reduces the level of proteinuria in the subject.

15. The use of claims 1-14, wherein the compound is to be administered by injection selected from intravenous, subcutaneous, intramuscular, intrathecal (IT), and intracerebroventricular (ICV).
16. The use of claim 15, wherein the administration is subcutaneous administration.